Purpose

: Bacteriuria may affect the response to adjuvant therapy in non-muscle invasive bladder cancer (NMIBC). The main aim of this study was to examine the effect of recurrent bacteriuria (RB) on the prognosis of NMIBC in women receiving intravesical therapy.

Materials and methods

: We designed a prospective observational study from 2012 to 2019. We included women with bladder cancer treated with transurethral resection of the bladder (TURB) and adjuvant intravesical treatment. Significant bacteriuria was defined as a presence in urine cultures at or above 100,000 colony-forming units per millilitre. The recurrent bacteriuria group included patients with significant bacteriuria in at least two determinations in 6 months or in 3 or more determinations in a year. The institutional board approved the study.

Results

: 136 patients diagnosed with NMIBC participate in the study, of whom 100 met the inclusion criteria. During follow-up, 48 were categorized in the RB group and 52 formed the non-bacteriuria group (NB).

RB group had a better outcome

: 8 patients (16.67%) experiencing a recurrence of the same grade, with no progression to a higher-grade tumour or muscle-invasive tumour. In the NB group, 18 (34.6%) patients presented a recurrence (p=0.001) and 22 (42.3%) progressed to a higher-grade tumour or muscular invasion (p=0.001). The presence of RB was identified as a predictor of good response in multivariate regression with a relative risk of 0.13 (p=0.018)

Conclusions

: Female patients with RB had a better response to adjuvant treatment for NMIBC. The RB group showed lower rates of tumour recurrences and progression.

MicroAbstract

: Bacteriuria may affect the response to adjuvant therapy in non-muscle invasive bladder cancer. We developed a prospective observational study including women with bladder cancer treated with intravesical treatment. The presence of significant bacteriuria was analysed. Female patients with RB had a better response to adjuvant treatment for NMIBC. The RB group showed lower rates of tumour recurrences and progression.

中文翻译：

---

复发性菌尿作为非肌层浸润性膀胱癌辅助治疗的预后标志物

目的

：菌尿可能影响非肌层浸润性膀胱癌 (NMIBC) 辅助治疗的反应。本研究的主要目的是探讨复发性菌尿 (RB) 对接受膀胱内治疗的女性 NMIBC 预后的影响。

材料和方法

：我们设计了一项 2012 年至 2019 年的前瞻性观察性研究。我们纳入了接受经尿道膀胱切除术 (TURB) 和辅助膀胱内治疗的膀胱癌女性。显着菌尿被定义为尿培养物中存在每毫升100,000个菌落形成单位或以上。复发性菌尿组包括在 6 个月内至少两次测定或一年内 3 次或以上测定中出现显着菌尿的患者。机构委员会批准了这项研究。

结果

：136 名诊断为 NMIBC 的患者参与了该研究，其中 100 名符合纳入标准。随访期间，48 例被归入 RB 组，52 例被归为非菌尿组 (NB)。

RB组有更好的结果

：8 名患者 (16.67%) 经历相同级别的复发，没有进展为更高级别的肿瘤或肌肉浸润性肿瘤。在 NB 组中，18 名 (34.6%) 患者出现复发 (p=0.001)，22 名 (42.3%) 患者进展为更高级别的肿瘤或肌肉侵犯 (p=0.001)。 RB 的存在被确定为多变量回归中良好反应的预测因子，相对风险为 0.13 (p=0.018)

结论

：女性 RB 患者对 NMIBC 辅助治疗有更好的反应。 RB 组的肿瘤复发和进展率较低。

微摘要

：菌尿可能影响非肌层浸润性膀胱癌辅助治疗的反应。我们开展了一项前瞻性观察研究，研究对象包括接受膀胱内治疗的膀胱癌女性。分析了显着菌尿的存在。女性 RB 患者对 NMIBC 辅助治疗有更好的反应。 RB 组的肿瘤复发和进展率较低。